AtriCure Names Two New Members to the Board of Directors
June 15 2021 - 7:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced that Deborah H. Telman and Maggie Yuen
have been elected to its Board of Directors.
Ms. Telman has spent over 20 years in senior executive roles at
global companies. She is Executive Vice President and General
Counsel for Organon (NYSE: OGN), a global healthcare company formed
in June 2021 through a spinoff from Merck (NYSE: MRK) (known as MSD
outside of the United States and Canada) to focus on improving the
health of women throughout their lives. Ms. Telman helped lead the
separation work that created a standalone company serving more than
140 markets with more than 60 medicines and products across a range
of therapeutic areas. Going forward she has responsibility for the
company’s worldwide legal affairs, compliance, and global
environmental health and safety. Before Organon, Ms. Telman was
General Counsel at Sorrento Therapeutics (Nasdaq: SRNE), where she
was responsible for mergers and acquisitions, licensing,
governance, finance, human resources, regulatory compliance, and
legal functions. Previously, she spent four years at Johnson
Controls International plc (NYSE: JCI) as Vice President and
General Counsel - Building Solutions, North America, and prior to
that she held executive roles at Abbott Laboratories (NYSE: ABT)
and The Boeing Company (NYSE: BA), and was a partner at Winston and
Strawn LLP.
“I’m looking forward to joining the board of AtriCure and
working with Mike and the rest of the management team to further
the company’s mission,” said Ms. Telman. “There is an incredible
opportunity to treat more patients with innovative therapies and
the company has many catalysts for continued growth.”
Ms. Yuen is currently Chief Financial Officer at Penumbra, Inc.
(NYSE: PEN) and is a seasoned executive with more than 20 years of
experience within the manufacturing, medical devices, and life
science industries. Over the course of her career, she has
developed financial and operational expertise at both multi-billion
dollar public companies and entrepreneurial start-up ventures.
Prior to Penumbra, she was Vice President of Finance and Divisional
Chief Financial Officer for the Genetic Science Division for Thermo
Fisher Scientific Inc. (NYSE: TMO) and was Chief Financial Officer
at Mirion Technologies. She has also held various roles at Boston
Scientific (NYSE: BSX), GLU Mobile, Lifescan Inc., Picker
International, Rockwell Automation, and Eaton Corporation.
“I am really excited about the opportunity to join AtriCure’s
Board,” said Ms. Yuen. “The company is well positioned to
capitalize on growth prospects and further the treatment of atrial
fibrillation and post-operative pain.”
“I am thrilled that Deb and Maggie have agreed to join the
AtriCure Board of Directors,” said Michael Carrel, President and
Chief Executive Officer. “They have been a part of some incredible
companies and have experience in leading by building scale through
periods of significant growth. Their expertise in financial
matters, compliance, regulatory, legal, commercial initiatives, and
corporate strategy will be additive to our company and our team.
They are two incredibly talented and capable leaders.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
Forward-Looking Statements
This press release contains “forward-looking statements”– that
is, statements related to future events that by their nature
address matters that are uncertain. This press release also
includes forward-looking projected financial information that is
based on current estimates and forecasts. Actual results could
differ materially. For details on the uncertainties that may cause
our actual results to be materially different than those expressed
in our forward-looking statements, visit
http://www.atricure.com/fls as well as our Annual Reports on Form
10-K and Quarterly Reports on Form 10-Q which contain risk factors.
We do not undertake to update our forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210615005012/en/
Angie Wirick Investor Relations Chief Financial Officer (513)
755-5334 awirick@atricure.com
Valerie Storch-Willhaus Media Relations Vice President,
Corporate Marketing and Communications (612) 605-3311
vstorch-willhaus@atricure.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024